BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 17, 2020
Product Development

Bumpy ride for debut of Verily’s COVID-19 screening platform

After California Gov. Gavin Newsom unveiled an online COVID-19 screening partnership with Verily Life Sciences at a press briefing Sunday, the system was unable to process some test requests Monday morning before becoming accessible in...
BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

Large diagnostics companies with COVID-19 testing capabilities weathered Monday’s sell-off better than biotechs developing therapies and vaccines for the virus. Major indexes fell due to continued fears over the COVID-19 outbreak and a steep drop...
BioCentury | Mar 10, 2020
Product Development

COVID-19 update: gaps persist between U.S. test capacity rhetoric, reality; BARDA funds Hologic’s high-throughput assay

COVID-19 testing capacity in the U.S. is ramping up slowly, but huge gaps remain between needs and capacity, and between government claims and reality. Delays in creating test capacity caused by incompetence at CDC and...
BioCentury | Mar 7, 2020
Product Development

Coronavirus crisis calls for competence, clarity and courage at the top

In times of crisis, societies need competence, clarity and courage from their leaders -- qualities that have been in short supply during the COVID-19 outbreak. Now more than ever, agencies like CDC and FDA need...
BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and Trademark Director David...
BC Extra | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
BioCentury | Oct 13, 2018
Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...
Items per page:
1 - 10 of 321
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 17, 2020
Product Development

Bumpy ride for debut of Verily’s COVID-19 screening platform

After California Gov. Gavin Newsom unveiled an online COVID-19 screening partnership with Verily Life Sciences at a press briefing Sunday, the system was unable to process some test requests Monday morning before becoming accessible in...
BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
BioCentury | Mar 10, 2020
Finance

Diagnostics companies survive Monday’s market rout

Large diagnostics companies with COVID-19 testing capabilities weathered Monday’s sell-off better than biotechs developing therapies and vaccines for the virus. Major indexes fell due to continued fears over the COVID-19 outbreak and a steep drop...
BioCentury | Mar 10, 2020
Product Development

COVID-19 update: gaps persist between U.S. test capacity rhetoric, reality; BARDA funds Hologic’s high-throughput assay

COVID-19 testing capacity in the U.S. is ramping up slowly, but huge gaps remain between needs and capacity, and between government claims and reality. Delays in creating test capacity caused by incompetence at CDC and...
BioCentury | Mar 7, 2020
Product Development

Coronavirus crisis calls for competence, clarity and courage at the top

In times of crisis, societies need competence, clarity and courage from their leaders -- qualities that have been in short supply during the COVID-19 outbreak. Now more than ever, agencies like CDC and FDA need...
BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and Trademark Director David...
BC Extra | Feb 20, 2019
Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
BioCentury | Oct 13, 2018
Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...
Items per page:
1 - 10 of 321